Neuren Pharmaceuticals (ASX: NEU) highlighted the robust performance of its partner, Acadia Pharmaceuticals (Nasdaq: ACAD), which reported US$348.4 million in net sales of DAYBUE (trofinetide) in 2024, a 97% increase from the previous year. Q4 2024 achieved a record US$96.7 million in sales, reflecting strong market adoption. With 70% of diagnosed Rett syndrome patients yet to try DAYBUE, significant growth potential remains.
Acadia is accelerating adoption by expanding its field force by 30%, enhancing patient support, and launching targeted Direct-to-Consumer campaigns. For 2025, Acadia projects US net sales between US$380 million and US$405 million, with the first Canadian sales expected in Q3 2025 and EU revenues anticipated through managed access programs ahead of a Q1 2026 approval. If Acadia meets its sales guidance, Neuren expects AU$56.2 million in royalties for 2024, up 110%, and AU$62-67 million in 2025. This continued growth strengthens Neuren’s financial outlook and global expansion strategy.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Mar 26, 2025
Mar 26, 2025
Mar 26, 2025
Mar 26, 2025
Mar 26, 2025
Mar 26, 2025
Mar 25, 2025
Mar 25, 2025
Mar 25, 2025
Mar 25, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
